By Chris Reidy, Globe Staff <\/p>\n
Foundation Medicine Inc. said that Bill Gates of Microsoft fame is among investors who expanded the Cambridge companys Series B financing round by an additional $13.5 million. <\/p>\n
Microsoft Corp. founder Bill Gates. (AP File Photo\/Ted S. Warren) <\/p>\n
Advances in understanding the human genome are having a dramatic impact on almost every area of medicine, Gates said in a statement. Foundation Medicines approach in harnessing the power of genomic data to improve care for cancer patients could represent an extremely important step forward in improving routine cancer care. <\/p>\n
Besides Gates, new investors included Evan Jones and Yuri Milner, said the company, which added that their investments bring the total raised in the round to $56 million. <\/p>\n
Foundation Medicines first product is called FoundationOne, and it is a genomic assay for all solid tumors that analyzes tumor DNA and provides a concise report to help doctors match patients with the targeted drugs or clinical trials best suited to treat their individual cancers, the company said in a press release. <\/p>\n
<\/p>\n
Continue reading here: <\/p>\n
Bill Gates invests in Foundation Medicine, which uses genome data for cancer diagnostics<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" By Chris Reidy, Globe Staff Foundation Medicine Inc. said that Bill Gates of Microsoft fame is among investors who expanded the Cambridge companys Series B financing round by an additional $13.5 million. Continue reading